

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-013APPLICATION NO.
09/927,703INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

DEC 07 2001

October 29, 2001

(Use several sheets if necessary)

APPLICANT
Junming Le, et al.FILING DATE
August 10, 2001GROUP
1642

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	4,603,106	07/29/86	Cerami et al.	435	7	
	AB	4,822,776	04/18/89	Cerami et al.	514	21	
	AC	5,658,570	08/19/97	Newman et al.	424	184.1	
	AD	5,750,105	5/12/98	Newman et al.	424	133.1	
	AE	5,231,024	7/27/93	Moeller et al.	435	240.27	
	AF	5,888,511	03/30/99	Skurkovich et al.	424	145.1	
	AG	5,958,413	09/28/99	Anagnostopoulos et al.	424	178.1	
	AH	5,993,833	11/30/99	DeLacharriere et al.	424	401	
	AI	5,342,613	08/30/94	Creaven et al.	424	85.1	
	AJ	6,190,691 B1	02/20/01	Mak	424	449	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	0212489A2	04 MAR 87	EPO			
	AM	0218868A2	22 APR 87	EPO			
	AN	0288088A2	26 OCT 88	EPO			
	AO	0308378A2	22 MAR 89	EPO			
	AP	0380068A1	01 AUG 90	EPO			
	AQ	0393438A3	24 OCT 90	EPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," <i>Nature</i> , 316:552-554 (1985).
	AS	Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," <i>Science</i> , 229:869-871 (1985).
	AT	Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> , 229:1202-1207 (1985).

EXAMINER

DATE CONSIDERED

PB 6/14/04

RECEIVED
DEC 10 2001
TECH CENTER 16012900

PTO-1449 REPRODUCED				ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 29, 2001 (Use several sheets if necessary)				APPLICANT Junming Le, et al.			
				FILING DATE August 10, 2001		GROUP 1642	
U. S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUP- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL2	0398327A1	22 NOV 90	EPO			
	AM2	0412486A1	13 FEB 91	EPO			
	AN2	0433900A1	26 JUN 91	EPO			
	AO2	0526905A2	10 FEB 93	EPO			
	AP2	WO91/02078	21 FEB 91	PCT			
	AQ2	WO92/07076	30 APR 92	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AU	Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. & Biophys. Res. Comm.</i> , 137(2):847-854 (1986).					
	AV	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. of Immun. Methods</i> , 96:57-62 (1987).					
	AW	Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> , 166:1280-1289 (1987).					
	AX	Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> , 6(3):305-311 (1987).					
	AY	Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , 6(4):359-370 (1987).					
	AZ	Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987).					
	AR2	Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987).					
	AS2	Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988).					
EXAMINER PB 6/14/01				DATE CONSIDERED			

RECEIVED

DEC 10 2001

TECH CENTER 1600 2900

DUPLICATE

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-013APPLICATION NO.
09/927,703INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

DEC 07 2001

October 29, 2001

(Use several sheets if necessary)

APPLICANT
Junming Le, et al.FILING DATE
August 10, 2001GROUP
1642

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL3 WO92/13095	06 AUG 92	PCT			
	AM3 0260610A2	23 MAR 88	EPO			
	AN3 91/09967	11 JUL 91	PCT			
	AO3 0351789A2	24 JAN 90	EPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AT2	Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988).
AU2	Di Giovine, Francesco, S. et al., "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988).
AV2	Collins, M.S. et al., "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of <i>Pseudomonas aeruginosa</i> ," Abstract E-63, Abstracts of Annual Meeting 1989.
AW2	Exley, A.R. et al., "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," <i>Medical Research Society</i> , Abstract 184, p. 50 (1989).
AX2	Cross, A.S. et al., "Pretreatment with Recombinant Murine Tumor Necrosis Factor α /Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," <i>J of Exp Med.</i> , 169:2021-2027 (1989).
AY2	Engelmann, Hartmut et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. of Bio. Chem.</i> , 264(20):11974-11980 (1989).
AZ2	Kawasaki, Hajime et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> , 57(10):3131-3135 (1989).

EXAMINER

M / 6/14/04

DATE CONSIDERED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703			
OIPE INFORMATION DISCLOSURE CITATION IN AN APPLICATION DEC 07 2001 October 29, 2001 (Use several sheets if necessary)		APPLICANT Junming Le, et al.					
		FILING DATE August 10, 2001		GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AP3	0350690A2	17 JAN 90	EPO			
	AQ3	90/00902	08 FEB 90	PCT			
	AL4	WO 92/11383	09 JUL92	PCT			
	AM4	WO 93/02108	4 FEB 93	PCT			
	AN4	WO 92/16553	19 MAR 92	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR3	Fong, Yuman et al., "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 β and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989).					
	AS2	Von Asmuth, E.J.U. et al., "Tumour Necrosis Factor Alpha (TNF- α) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> , 32:313-319 (1990).					
	AT3	Herve, P. et al., "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," <i>Abstract 3.25, Lymphoma Res.</i> 9:591 (1990).					
	AU3	Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor- α in Experimental Gram-Negative Shock," <i>J. of Infectious Diseases</i> , 162:421-427 (1990).					
	AV3	Opal, Steven M. et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. of Infectious Diseases</i> , 161:1148-1152 (1990).					
	AW3	Tavernier, Jan et al., "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> , 211:493-501 (1990).					
	AX3	Lucas, R. et al., "Generation and characterization of a neutralizing rat anti-rm TNF- α monoclonal antibody," <i>Immunology</i> , 71:218-223 (1990).					
	AY3	Hinshaw, L.B. et al., "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292 (1990).					
EXAMINER M 6/4/04				DATE CONSIDERED			

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 29, 2001 (Use several sheets if necessary)		APPLICANT Junming Le, et al.					
		FILING DATE August 10, 2001		GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AO4	0 867 509 A2	30 SEP 98	EPO			
	AP4	0 861 850 A1	02 SEP 98	EPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AZ3	Nophar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990).					
	AR4	Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990).					
	AS4	Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990).					
	AT4	Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990).					
	AU4	Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990).					
	AV4	Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E ₂ Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990).					
	AW4	Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990).					
	AX4	Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α : In Vitro and In Vivo Application," <i>Cytokine</i> , 2(3):162-169 (1990).					
	AY4	Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990).					
EXAMINER MB 6/14/04				DATE CONSIDERED			

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 29, 2001 (Use several sheets if necessary)		APPLICANT Junming Le, et al.					
		FILING DATE August 10, 2001		GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AQ4	0 869 179 A1	07 OCT 98	EPO			
	AL5	0 870 827 A2	14 OCT 98	EPO			
	AM5	0 706 795 A2	17 APR 96	EPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AZ4	Galloway, Cynthia J. et al., "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," <i>J. of Immunological Methods</i> , 140:37-43 (1991).					
	AR5	Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (1991).					
	AS5	Aderka, Dan et al., "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," <i>Israel J. Med. Sci.</i> , 28(2):126-130 (1992).					
	AT5	Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," <i>ASM News</i> , 58(9):479-482 (1992).					
	AU5	Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," <i>TBTECH</i> , 11:42-44 (1993).					
	AV5	Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," <i>N.E. Journal of Medicine</i> , 328(20):1471-1477 (1993).					
	AW5	Aggarwal, Bharat B. et al., "Human Tumor Necrosis Factor Production, Purification and Characterization," <i>J. of Biol. Chem.</i> , 260(4):2345-2354 (1985).					
	AX5	Beutler, B. et al., "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," <i>J. Exp. Med.</i> , 161:984-995 (1985).					
	AY5	Echtenacher, Bernd et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. of Immunology</i> , 145(11):3762-3766 (1990).					
	AZ5	Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," 4Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991).					
EXAMINER N 6/14/01				DATE CONSIDERED			

RECEIVED

DEC 10 2001


TECH CENTER 1600/2900

DUPLICATE

PTO-1449 REPRODUCED				ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION DEC 07 2001 October 29, 2001 (Use several sheets if necessary)				APPLICANT Junming Le, et al.			
				FILING DATE August 10, 2001		GROUP 1642	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AN5	0 706 795 A3	17 DEC 97	EPO			
	AO5	WO98/51344	19 NOV 98	PCT			
	AP5	WO00/62790	26 OCT 00	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR6	Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, Endotoxemia & Sepsis Conference (1991).					
	AS6	Genebank Accession, No. N90300 (1989, November 1).					
	AT6	Genebank Accession, No. M32046 (1990, June 15).					
	AI16	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies", Behring Inst. Mitt, No. 78:118-132 (1985).					
	AV6	Partsch, G., et al., "Upregulation of Cytokine Receptors sTNF-R55, sTNF-R75, and sIL-2R in Psoriatic Arthritis Synovial Fluid," J. of Rheumatology, 25:1 105-110 (1998).					
	AW6	Omulecki, A., et al., "Is Pentoxifylline Effective in the Treatment of Psoriasis?", J. of the Am. Academy of Dermatology, 34:4 714-715.					
	AX6	Sagawa, Y., et al., "Is Sustained Production of Tumor Necrosis Factor- α Relevant to the Development of Pustular Psoriasis?," Dermatology, 187:81-83 (1993)					
	AY6	Mease, P.J., et al. "Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: a Randomised Trial," The Lancet, 356:385-390 (2000).					
	AZ6	Chaudhari, U., et al., "Efficacy and Safety of Infliximab Monotherapy for Plaque-Type Psoriasis: A Randomised Trial," The Lancet, 357:1842-1847 (2001).					
	AR7	Creaven, P.J., et al., "Response to Tumor Necrosis Factor in Two Cases of Psoriasis," J. of Am. Acad. of Dermatology, 24:5(1) 735-737 (1991).					
	AS7	Oh, C.J., et al., "Treatment with Anti-Tumor Necrosis Factor α (TNF- α) Monoclonal Antibody Dramatically Decreases the Clinical Activity of Psoriasis Lesions," J. Am. Acad. Dermatology, 829-830 (2000).					
EXAMINER PG 6/4/04				DATE CONSIDERED			

[X] Applicant requests that the following pending applications be considered:

Examiner's
Initials



~~U.S. Patent Application No. 10/227,488, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed August 23, 2002, Docket No.: 0975.1005-025~~

Patent Examiner
Examiner

6/14/04
Date

- [X] The specification for the above cited co-pending application is identical to the present specification (09/927,703). Therefore, only a copy of the current claims for this application is enclosed. Copies of the specification of the co-pending applications will be provided upon request.
- [] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment.

- [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders
Deirdre E. Sanders
Registration No.: 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated: October 9, 2002

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references are enclosed except those entered in prior applications, U.S. Application No. 09/756,398 and Application No. 09/133,119, to which priority under 35 U.S.C. 120 is claimed. The earlier applications contains copies of the cited references.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.

- ☒ Applicant requests that the following pending applications be considered:

Examiner's
InitialsPS

~~U.S. Patent Application No. 09/756,398, by Junming Le, Jan Vileck, Peter Daddona,
John Ghayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.:
0975.1005-006~~

Phuong Gamba 6/14/04

MC

~~U.S. Patent Application No. 09/756,161, by Junming Le, Jan Vilcek, Peter Daddona,
John Ghrayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.:
0975.1005-007~~

MC

~~U.S. Patent Application No. 09/756,301, by Junming Le, Jan Vilcek, Peter Daddona,
John Ghrayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.:
0975.1005-008~~

Plaus Gaurza
Examiner

6/14/04
Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☒ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. 09/756,398, to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders
Deirdre E. Sanders
Registration No.: 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated: October 29, 2001

09/27,703

-2-

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. 09/756,398, to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.
- ☒ Applicant requests that the following pending applications be considered:

Examiner's
Initials

U.S. Patent Application No. 09/766,535, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 18, 2001, Docket No.: 0975.1005-010

U.S. Patent Application No. 09/897,724, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed July 2, 2001, Docket No.: 0975.1005-012

U.S. Patent Application No. 10/010,229, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed December 7, 2001, Docket No.: 0975.1005-014

U.S. Patent Application No. 10/043,450, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-015

Received from <1 978 341 0136> at 9/29/03 12:11:47 PM [Eastern Daylight Time]

Patricia G. G. 6/14/04

09/27,703

-3-

M

U.S. Patent Application No. 10/044,534, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-016

M

U.S. Patent Application No. 10/043,432, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-017

M

U.S. Patent Application No. 10/043,436, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-018

Philip G. Ganger
Examiner

6/14/04
Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☒ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. 09/756,398, to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By

Deirdre E. Sanders

Deirdre E. Sanders

Registration No.: 42,122

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated:

March 27, 2002

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. (), to which priority under 35 U.S.C. 120 is claimed. The earlier application contains copies of the cited references.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.

☒ Applicant requests that the following pending applications be considered:

Examiner's
Initials



U.S. Patent Application No. 10/176,460, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed June 20, 2002, Docket No.: 0975.1005-019



U.S. Patent Application No. 10/187,121, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-020



6/14/04

pi
~~U.S. Patent Application No. 10/186,559, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-021~~

f
~~U.S. Patent Application No. 10/198,845, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 18, 2002, Docket No.: 0975.1005-022~~

f
~~U.S. Patent Application No. 10/200,795, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 22, 2002, Docket No.: 0975.1005-023~~

Me
~~U.S. Patent Application No. 10/208,145, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 29, 2002, Docket No.: 0975.1005-024~~

Robert G. Gaudier
Examiner

6/14/04
Date

- [X] The specification for the above cited co-pending applications is identical to the present specification (09/927,703). Therefore, only a copy of the current claims for each application is enclosed. Copies of the specifications of the co-pending applications will be provided upon request.
- [] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

09/27,703

-2-

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references are enclosed except those entered in prior applications, U.S. Application No. 09/756,398 and Application No. 09/133,119, to which priority under 35 U.S.C. 120 is claimed. The earlier applications contains copies of the cited references.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.
- ☒ Applicant requests that the following pending applications be considered:

Examiner's
Initials

U.S. Patent Application No. 09/756,398, by Junming Lo, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-006

Philip Grana 6/14/04

9/29/03


-3-



~~U.S. Patent Application No. 09/756,161, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975-1005-007~~

~~U.S. Patent Application No. 09/756,301, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975-1005-008~~


Examiner


Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☒ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. 09/756,398, to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.


It is requested that the information disclosed herein be made of record in this application.

Method of payment:


- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 
Deirdre E. Sanders
Registration No.: 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated: 

Received from <1 978 341 0136> at 9/29/03 12:11:47 PM [Eastern Daylight Time]

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. 09/756,398, to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.
- ☒ Applicant requests that the following pending applications be considered:

Examiner's
Initials

MU

~~U.S. Patent Application No. 09/766,535, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 18, 2001, Docket No.: 0975.1005-010~~

~~U.S. Patent Application No. 09/897,724, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed July 2, 2001, Docket No.: 0975.1005-012~~

~~U.S. Patent Application No. 10/010,229, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed December 7, 2001, Docket No.: 0975.1005-014~~

~~U.S. Patent Application No. 10/043,450, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-015~~

Junming Le 6/14/04

U.S. Patent Application No. 10/044,534, by Junming Le, Jan Vilcek, Peter Daddona,
John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.:
0975.1005-016

U.S. Patent Application No. 10/043,432, by Junming Le, Jan Vilcek, Peter Daddona,
John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.:
0975.1005-017

U.S. Patent Application No. 10/043,436, by Junming Le, Jan Vilcek, Peter Daddona,
John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.:
0975.1005-018

Philip C. Mober
Examiner

6/14/04
Date

- [] A copy of each above-cited application, including the current claims, is enclosed.
- [X] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. 09/756,398, to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,


HAMILTON, BROOK, SMITH & REYNOLDS, P.C.


By Deirdre E. Sanders

Deirdre E. Sanders
Registration No.: 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136






Concord, Massachusetts 01742-9133

Dated: March 29, 2002

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703				
 INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 29, 2002 (Use several sheets if necessary)		APPLICANT Junming Le, et al.		RECEIVED APR 03 2002 TECH CENTER 1508 CD 2900 FILING DATE IF APPROPRIATE				
		FILING DATE August 10, 2001				GROUP 1642		
U. S. PATENT DOCUMENTS								
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS			
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATI ON YES NO	
<i>M</i>	AQ5	WO91/09967	11 JUL 91	PCT				
<i>M</i>	AL6	0486526B2	07 MAR 01	EPO				
<i>M</i>	AM6	WO92/02190	10 JUN 92	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
<i>M</i>	AT7	Whittle, Nigel, et al., "Construction and Expression of a CDR-Grafted Anti-TNF Antibody," <i>J. Cell Biochem</i> , Supl. 13A:96 (1989).						
<i>M</i>	AU7	Gorman, S.D. and Clark, M.R., "Humanisation of monoclonal antibodies for therapy," <i>Sem Immunol</i> , 2:457-466 (1990).						
<i>M</i>	AV7	Starnes, H. Fletcher, Jr., et al., "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal <i>Escherichia Coli</i> Infection and Lethal Tumor Necrosis Factor Challenge in Mice," <i>J Immunol</i> , 145:4185-4191 (1990).						
EXAMINER <i>Philip Ganga</i>				DATE CONSIDERED <i>6/14/04</i>				

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703	
		APPLICANT Junming Le, et al.			
		FILING DATE August 10, 2001		GROUP 1642	
U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
M	AW7	Duncombe, Andrew S. et al., "Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia," <i>J Immunol</i> , 143:3828-3834 (1989).			
I	AX7	Aderka, Dan et al., "IL-6 Inhibits Lipopolysaccharide-Induced tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice," <i>J Immunol</i> , 143:3517-3523 (1989).			
	AY7	Aderka, Dan, "Role of Tumor Necrosis Factor in the Pathogenesis of Intravascular Coagulopathy of Sepsis: Potential New Therapeutic Implications," <i>Isr J Med Sci</i> , 27:52-60 (1991).			
	AZ7	Lassalle, Ph., et al., "Potential Implication of Endothelial Cells in Bronchial Asthma," <i>Int Arch Allergy Appl Immunol</i> , 94:233-238 (1991).			
	AR8	Fong, Yuman and Lowry, Stephen F., "Tumor Necrosis Factor in the Pathophysiology of Infection and Sepsis," <i>Clin Immunol Immunopathol</i> , 55:157-170 (1990).			
	AS8	Eck, Michael J. and Sprang, Stephen R., "The Structure of Tumor Necrosis Factor- α at 2.6 Å Resolution," <i>J Biol Chem</i> , 264:17595-17605 (1989).			
	AT8	Gillies, Stephen D. et al., "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," <i>J Immunol Methods</i> , 125:191-202 (1989).			
M	AU8	Kameyama, Koh-zoh, et al., "Convenient plasmid vectors for construction of chimeric mouse/human antibodies," <i>FEBS Lett</i> , 244:301-306 (1989).			
EXAMINER		DATE CONSIDERED			
Phung Gamba		6/14/04			

RECEIVED
 APR 03 2002
 TECH CENTER 1600/2900
 FILING DATE
 IF
 APPROPRIATE

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703			
 INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 29, 2002 (Use several sheets if necessary)		APPLICANT Junming Le, et al.		TECH CENTER 1600/2002 APR 03 2002 RECEIVED			
		FILING DATE August 10, 2001				GROUP 1642	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AV8	Hayashi, H. et al., "An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody," Recent Adv. Chemother, 820-821 (1985).					
	AW8	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," J Immunol Methods, 96:57-62 (1987).					
	AX8	Sunahara, N. et al., "Simple enzyme immunoassay methods for recombinant human tumor necrosis factor α and its antibodies using a bacterial cell wall carrier," J Immunol Methods, 109:203-214 (1988).					
EXAMINER							
		DATE CONSIDERED 6/14/04					

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
AN APPLICATION

AUG 28 2002

August 23, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
0975.1005-013

APPLICATION NO
09/927,703

APPLICANT
Junming Le et al.

FILING DATE
August 10, 2001

GROUP
1644

AUG 29 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AK	5,223,395	06/29/93	Gero	435	71	
	AA2	5,436,154	07/25/95	Barbanti et al.	435	240.27	
	AB2	5,654,407	08/05/97	Boyle et al.	530	388.15	
	AC2	5,700,788	12/23/97	Mongelli et al.	514	91	
	AD2	5,730,975	03/24/98	Hotamisligil et al.	424	130.1	
	AE2	5,741,488	04/21/98	Feldman et al.	424	154.1	
	AF2	5,776,947	07/07/98	Kroemer et al.	514	312	
	AG2	6,015,558	01/18/00	Hotamisligil et al.	424	142.1	
	AH2	6,172,202 B1	01/09/01	Marcucci et al.	530	406	
	AI2	6,194,451 B1	02/27/01	Alpegiani et al.	514	459	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AN6	0 288 088 B1	26 OCT 88	EPO			
	AO6	0 351 789 B1	24 JAN 90	EPO			
	AP6	0 453 898 A2	30 OCT 91	EPO			X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AY8	Oliff, A., et al., "Tumors Secreting Human TNF/Cachectin Induce Cachexia in Mice," Cell, 50:555-563 (1987).
AZ8	Mule, J.J., et al., "Antitumor Activity of Recombinant Interleukin 6 in Mice," The Journal of Experimental Medicine, 171:629-636 (1990).
AR9	Luetting, B., et al., "Evidence For The Existence Of Two Forms Of Membrane Tumor Necrosis Factor: An Integral Protein And A Molecule Attached To Its Receptor," The Journal of Immunology, 143:4034-4038 (1989).
AS9	Barbuto, J.A.M., et al., "Production of neutralizing antibodies to tumor necrosis factor by human tumor-infiltrating B lymphocytes," Proceedings of the American Association for Cancer Research, 34:487, Abstract 2904, (1993).


EXAMINER

Phuc G. Au

DATE CONSIDERED

6/14/04


PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION August 23, 2002 (Use several sheets if necessary)		APPLICANT Junming Le et al.		FILING DATE August 10, 2001 GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AO6	0 585 705 A1	09 MAR 94	EPO			
	AL7	0 614 984 A2	14 SEP 94	EPO			
	AM7	0 663 836 B1	26 JUL 95	EPO			
	AN7	WO 89/08460	21 SEP 89	PCT			
	AO7	WO 90/01950	08 MAR 90	PCT			
	AP7	WO 91/04054	04 APR 91	PCT			
	AO7	WO 92/01472	06 FEB 92	PCT			
	AL8	WO 93/11236	10 JUN 93	PCT			
	AM8	WO 94/08609	28 APR 94	PCT			
	AN8	WO 94/08619	28 APR 94	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AT9	Bendtzen, K., et al., "Auto-Antibodies To IL-1 α and TNF α In Normal Individuals And In Infectious And Immunoinflammatory Disorders," <i>The Physiological and Pathological Effects of Cytokines</i> , 10B:447-452 (1990).					
	AU9	Fomsgaard, A., et al., "Auto-Antibodies To Tumour Necrosis Factor α In Healthy Humans And Patients With Inflammatory Diseases And Gram-Negative Bacterial Infections," <i>Scand. J. Immunol.</i> , 30:219-223 (1989).					
	AV9	James, K. and Bell, G.T., "Human Monoclonal Antibody Production Current Status And Future Prospects," <i>Journal of Immunological Methods</i> , 100:5-40 (1987).					
	AW9	Alberts, B. et al., <i>Molecular Biology of the Cell</i> , Garland Publishing Inc., pp 182-183 (1983).					
	AX9	Simpson, S.Q., et al., "Role Of Tumor Necrosis Factor In Sepsis And Acute Lung Injury," <i>Critical Care Clinics</i> , 5:27-47 (1989).					
	AY9	Bendtzen, K., et al., "Native inhibitors (autoantibodies) of IL-1 α and TNF," <i>Immunology Today</i> , 10(7):222 (1989).					
EXAMINER <i>Humphreys</i>				DATE CONSIDERED 6/14/04			



AUG 29 2002
 TECH CENTER 1600/2800

RECEIVED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013	APPLICATION NO. 09/927,703
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT Junming Le et al.	
August 23, 2002		FILING DATE August 10, 2001	GROUP 1642
(Use several sheets if necessary)			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AZ9	Davenport, C., et al., "Stimulation Of Human B Cells Specific For Candida Albicans For Monoclonal Antibody Production," <i>FEMS Microbiol Immunol</i> , 4(6):335-343 Abstract (1992).		
AR10	Pennica, D., et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> , 312(20/27):724-729 (1984).		
AS10	Gray, P.W., et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," <i>Nature</i> , 312(20/27):721-724 (1984).		
AT10	Petersen, C.M., et al., "Bioactive human recombinant tumor necrosis factor- α : an unstable dimer?," <i>Eur. J. Immunol.</i> , 19:1887-1894 (1989).		
AU10	Smith, C. A., et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins," <i>Science</i> , 248:1019-1023 (1990).		
AV10	Brennan, F.M., et al., "Inhibitory Effect Of TNF α Antibodies On Synovial Cell Interleukin-1 Production In Rheumatoid Arthritis," <i>The Lancet</i> , 244-247 (1989).		
AW10	Hahn, T., et al., "Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein," <i>Proc. Natl. Acad. Sci. USA</i> 82:3814-3818 (1985).		
AX10	Grau, G.E., et al., "Tumor Necrosis Factor (Cachectin) as an Essential Mediator in Murine Cerebral Malaria," <i>Science</i> , 237:1210-1212 (1987).		
AY10	Barbanti, E., et al., "A high-affinity neutralizing anti-human TNF- α monoclonal antibody that cross-reacts with human TNF- β ," <i>Abstracts</i> , March 6th-9th (1991).		
AZ10	Jones, E.Y., et al., "Structure of tumour necrosis factor," <i>Nature</i> , 338:225-228 (1989).		
AR11	Clark, W. R., "Types of Antibody Reactions," In <i>The Experimental Foundations of Modern Immunology</i> , (NY: John Wiley & Sons, Inc.) 4th Ed., pp 143-155 (1991).		
AS11	Beutler, B., et al., "Cachectin and tumour necrosis factor as two sides of the same biological coin," <i>Nature</i> , 320:584-588 (1986).		
AT11	Folks, T. M., et al., "Tumor Necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone," <i>Proc. Natl. Acad. Sci. USA</i> , 86:2365-2358 (1989).		
AU11	Hird, V., et al., "Immunotherapy with Monoclonal Antibodies," In <i>Genes and Cancer</i> (John Wiley & Sons, Ltd.) (1990).		
AV11	Rhein, R., "Another sepsis drug down-Immunex' TNF receptor," <i>Biotechnology Newswatch</i> , Monday, October 4, 1993, pp. 1,3.		
EXAMINER Phuong G. M. B. 6/14/04			DATE CONSIDERED



TECH CENTER 1600/2900

AUG 29 2002



Sheet 4 of

TECH CENTER 1600/2900

AUG 29 2002

RECEIVED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013	APPLICATION NO. 09/927,703
INFORMATION DISCLOSURE CITATION IN AN APPLICATION August 23, 2002 (Use several sheets if necessary)		APPLICANT Junming Le et al.	
		FILING DATE August 10, 2001	GROUP 1642
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AW11	Boyle, P., et al., "A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- α ," <i>Cellular Immunology</i> , 152:556-568 (1993).		
AX11	Boyle, P., et al., "The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF α on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope," <i>Cellular Immunology</i> , 152:569-581 (1993).		
AY11	Sheehan, K.C.F., et al., "Generation And Characterization Of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors," <i>The Journal of Immunology</i> , 142(11):3884-3893 (1989).		
AZ11	Jacob, C.O., et al., "Tumour necrosis factor- α in murine autoimmune 'lupus' nephritis," <i>Nature</i> , 331:356-358 (1988).		
EXAMINER <i>Junming Le</i>		DATE CONSIDERED <i>6/14/02</i>	

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION OCT 15 2002 October 9, 2002 (Use several sheets if necessary)				ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703	
				APPLICANT Junming Le et al.			
				FILING DATE August 10, 2001		GROUP 1642	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AJ2		4,816,567	03/28/89	Cabilly et al.			
AK2		5,075,236	12/24/91	Yone et al.			
AA3		5,959,087	09/28/99	Rathjen et al.			
AB3		5,360,716	11/01/94	Ohmoto, Y. et al.			
					RECEIVED OCT 16 2002 TECH CENTER 1600/2900		
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AO8	WO92/01059	23 JAN 92	PCT			
	AP8	02-227095	10 SEP 90	JP			X
	AQ8	61-047500	07 MAR 86	JP			X
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR12	Yan, L. et al., "Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor Alpha", <i>Chinese J. Biotechnology</i> , 7(2):121-126 (1991).					
	AS12	Mateo, C. et al., "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity", <i>Hybridoma</i> , 19(6):463-471 (2000).					
	AT12	Paul, W.E. (Ed.), <i>Fundamental Immunology</i> , 3 rd Edition, Pub. Raven Press Ltd., pp. 292-293 (1993).					
	AU12	Borrebaeck, C.A.K. (Ed.), <i>Antibody Engineering</i> , 2 nd Edition, Pub. Oxford University Press, p. 291 (1995).					
	AV12	Socher, S. et al., "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor", <i>Proc. Natl. Acad. Sci., USA</i> 84:8829-8833 (1987).					
	AW12	Goh, C., "Tumour Necrosis Factors in Clinical Practice", <i>Annals of the Academy of Medicine</i> , 19(2):235-239 (1990).					
EXAMINER 				DATE CONSIDERED 6/14/04			

DOC ID NO.: :OPMA\MHODMA\jman 251118;1

Sheet 1 of 7

PTO-1449 REPRODUCED				ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 29, 2001 (Use several sheets if necessary)				APPLICANT Junming Le, et al.			
				FILING DATE August 10, 2001		GROUP 1642	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
M	AA	4,603,106	07/29/86	Cerami et al.	435	7	
	AB	4,822,776	04/18/89	Cerami et al.	514	21	
	AC	5,658,570	08/19/97	Newman et al.	424	184.1	
	AD	5,750,105	5/12/98	Newman et al.	424	133.1	
	AE	5,231,024	7/27/93	Moeller et al.	435	240.27	
	AF	5,888,511	03/30/99	Skurkovich et al.	424	145.1	
	AG	5,958,413	09/28/99	Anagnostopoulos et al.	424	178.1	
	AH	5,993,833	11/30/99	DeLacharriere et al.	424	401	
	AI	5,342,613	08/30/94	Crcaven et al.	424	85.1	
	AJ	6,190,691 B1	02/20/01	Mak	424	449	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	0212489A3	04 MAR 87	EPO			
	AM	0218868A2	22 APR 87	EPO			
	AN	0288068A2	26 OCT 88	EPO			
	AO	0308378A2	22 MAR 89	EPO			
	AP	0380068A1	01 AUG 90	EPO			
	AQ	0393438A3	24 OCT 90	EPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR	Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," <i>Nature</i> , 316:552-554 (1985).					
	AS	Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," <i>Science</i> , 229:869-871 (1985).					
	AT	Morrison, Shorie L., "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> , 229:1202-1207 (1985).					
EXAMINER Henry G. Gwiler				DATE CONSIDERED 6/14/04			

Sheet 2 of 7

PTG-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 29, 2001 (Use several sheets if necessary)		APPLICANT Junming Le, et al.					
		FILING DATE August 10, 2001		GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL2	0398327A1	22 NOV 90	EPO			
	AM2	0412486A1	13 FEB 91	EPO			
	AN2	0433900A1	26 JUN 91	EPO			
	AO2	0526905A2	10 FEB 93	EPO			
	AP2	WO91/02078	21 FEB 91	PCT			
	AQ2	WO92/07076	30 APR 92	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AU	Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. & Biophys. Res. Comm.</i> , 137(2):847-854 (1986).					
	AV	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. of Immun. Methods</i> , 96:57-62 (1987).					
	AK	Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> , 166:1280-1289 (1987).					
	AX	Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> , 6(3):305-311 (1987).					
	AY	Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , 6(4):359-370 (1987).					
	AZ	Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987).					
	AR2	Tracay, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987).					
	AS2	Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988).					
EXAMINER Philip G. Lumb				DATE CONSIDERED 6/14/07			

Sheet 3 of 7

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 29, 2001 (Use several sheets if necessary)		APPLICANT Junming Le, et al.					
		FILING DATE August 10, 2001		GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAM- INER INIT- IAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AM3	WO92/13095	06 AUG 92	PCT			
	AM3	0260610A2	23 MAR 88	EPO			
	AN3	91/09967	11 JUL 91	PCT			
	AO3	0351789A2	24 JAN 90	EPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AT2	Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988).					
	AU2	Di Giovine, Francesco, S. et al., "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988).					
	AV2	Collins, M.S. et al., "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of <i>Pseudomonas aeruginosa</i> ," Abstract E-63, <i>Abstracts of Annual Meeting 1989</i> .					
	AW2	Exley, A.R. et al., "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," <i>Medical Research Society, Abstract 184</i> , p. 50 (1989).					
	AX2	Cross, A.S. et al., "Pretreatment with Recombinant Murine Tumor Necrosis Factor α /Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," <i>J of Exp Med.</i> , 169:2021-2027 (1989).					
	AY2	Engelmann, Hartmut et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. of Bio. Chem.</i> , 264(20):11974-11980 (1989).					
	AZ2	Kawasaki, Hajime et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> , 57(10):3131-3135 (1989).					
EXAMINER Patricia G. Gans				DATE CONSIDERED 6/14/04			

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT Junming Le, et al.			
October 29, 2001 (Use several sheets if necessary)		FILING DATE August 10, 2001		GROUP 1642	
U.S. PATENT DOCUMENTS					
EXAM- INER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS
	AP3 0350690A2	17 JAN 90	EPO		
	AQ3 90/00902	08 FEB 90	PCT		
	AL4 WO 92/11383	09 JUL 92	PCT		
	AN4 WO 93/02108	4 FEB 93	PCT		
	AN4 WO 92/16553	19 MAR 92	PCT		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
AR3	Fong, Yuman et al., "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 β and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989).				
AN3	Von Asmuth, E.J.U. et al., "Tumour Necrosis Factor Alpha (TNF- α) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> , 32:313-319 (1990).				
AT3	Herve, P. et al., "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," Abstract 3.25, <i>Lymphoma Res.</i> 9:591 (1990).				
AU3	Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor- α in Experimental Gram-Negative Shock," <i>J. of Infectious Diseases</i> , 162:421-427 (1990).				
AV3	Opal, Steven M. et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. of Infectious Diseases</i> , 161:1148-1152 (1990).				
AW3	Tavernier, Jan et al., "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> , 211:493-501 (1990).				
AK3	Lucas, R. et al., "Generation and characterization of a neutralizing rat anti-rm TNF- α monoclonal antibody," <i>Immunology</i> , 71:218-223 (1990).				
AY3	Hinshaw, L.B. et al., "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292 (1990).				
EXAMINER <i>Patricia C. Mabel</i>			DATE CONSIDERED 6/14/04		

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975,1005-013		APPLICATION NO. 09/927,703			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 29, 2001 (Use several sheets if necessary)		APPLICANT Junming Le, et al.					
		FILING DATE August 10, 2001		GROUP 1642/			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AM	0 867 509 A2	30 SEP 98	EPO			
	AP4	0 861 950 A1	02 SEP 98	EPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A53	Nophar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990).					
	LM	Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990).					
	A54	Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990).					
	AT4	Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990).					
	AU-1	Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990).					
	AV4	Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E ₂ Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990).					
	AW6	Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990).					
	AX6	Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α : In Vitro and In Vivo Application," <i>Cytokine</i> , 2(3):162-169 (1990).					
	AY1	Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990).					
EXAMINER <i>Arthur K. Kung</i>				DATE CONSIDERED 6/17/04			

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-013		APPLICATION NO. 09/927,703			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 29, 2001 (Use several sheets if necessary)		APPLICANT Junming Le, et al.					
		FILING DATE August 10, 2001		GROUP 16429			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	ANG	0 706 795 A3	17 DEC 97	EPO			
	AOS	W098/51344	19 NOV 98	PCT			
	APS	W000/62790	26 OCT 00	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR6	Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, Endotoxemia & Sepsis Conference (1991).					
	AS5	Genebank Accession, No. N90300 (1989, November 1).					
	AT6	Genebank Accession, No. M32046 (1990, June 15).					
	AUS	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies", Behring Inst. Mitt, No.78:118-132 (1985).					
	AV6	Partsch, G., et al., "Upregulation of Cytokine Receptors sTNF-R55, sTNF-R75, and sIL-2R in Psoriatic Arthritis Synovial Fluid," J. of Rheumatology, 25:1 105-110 (1998).					
	AW6	Omulecki, A., et al., "Is Pentoxifylline Effective in the Treatment of Psoriasis?", J. of the Am. Academy of Dermatology, 34:4 714-715.					
	AX6	Sagawa, Y., et al., "Is Sustained Production of Tumor Necrosis Factor- α Relevant to the Development of Pustular Psoriasis?", Dermatology, 187:81-83 (1993).					
	AY6	Moase, P.J., et al. "Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: a Randomised Trial," The Lancet, 356:385-390 (2000).					
	AZ6	Chaudhari, U., et al., "Efficacy and Safety of Infliximab Monotherapy for Plaque-Type Psoriasis: A Randomised Trial," The Lancet, 357:1842-1847 (2001).					
	AR7	Creaven, P.J., et al., "Response to Tumor Necrosis Factor in Two Cases of Psoriasis," J. of Am. Acad. of Dermatology, 24:5(1) 735-737 (1991).					
	AS7	Oh, C.J., et al., "Treatment with Anti-Tumor Necrosis Factor α (TNF- α) Monoclonal Antibody Dramatically Decreases the Clinical Activity of Psoriasis Lesions," J. Am. Acad. Dermatology, 829-830 (2000).					
EXAMINER Pitump Gnaugel				DATE CONSIDERED 6/14/04			

Sheet 3 of 3

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975,1005-013		APPLICATION NO. 09/927,703			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 29, 2002 (Use several sheets if necessary)		APPLICANT Junming I.e, et al.					
		FILING DATE August 10, 2001		GROUP 16424			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AV8	Hayashi, H. et al., "An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody," <i>Recent Adv. Chemother</i> , 820-821 (1985).					
	AW8	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J Immunol Methods</i> , 96:57-62 (1987).					
	AX8	Sunahara, N. et al., "Simple enzyme immunoassay methods for recombinant human tumor necrosis factor - and its antibodies using a bacterial cell wall carrier," <i>J Immunol Methods</i> , 109:203-214 (1988).					
EXAMINER		DATE CONSIDERED					
P. H. G. G. G.		6/24/04					